GILD Gilead Sciences Inc.

68.48
-0.36  -1%
Previous Close 68.84
Open 68.75
Price To Book 3.97
Market Cap 87,304,878,080
Shares 1,274,896,000
Volume 6,293,231
Short Ratio
Av. Daily Volume 6,510,437

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 3 enrolment to be completed 2H 2020.
Cilofexor (GS-9674)
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 3Q 2019.
GS-5734
Ebola
sNDA filed April 5, 2019. Likely PDUFA date under priority review of October 4, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 data due 1H 2020.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data April 25, 2019 did not meet primary endpoint.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 data due 2Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Phase 2 data due 3Q 2019.
Axicabtagene ciloleucel - (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment to be completed 3Q 2019.
Axicabtagene ciloleucel - (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 data due 2Q 2019.
Axicabtagene ciloleucel - (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 1/2 data due 4Q 2019.
Axicabtagene ciloleucel (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 data due 4Q 2019.
Axicabtagene ciloleucel (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 48-week data due 4Q 2019.
Selonsertib + Cilofexor (GS-9674) combo
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 3Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 4Q 2019.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2b 48-week data due 4Q 2019.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial to be initiated 3Q 2019.
Selonsertib (GS-4997)
Diabetic kidney disease
Phase 1 initial data due 1H 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-11)
Phase 2 data due 2Q 2019.
GS-9688
HBV
Phase 2 trial to be initiated 4Q 2019.
Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)
Phase 2 enrolment to be completed 1H 2020.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial to be initiated 3Q 2019.
GS-4875
Ulcerative Colitis

Latest News

  1. The 10 Biggest Biotech Stocks
  2. What to Expect from Johnson & Johnson and Gilead Sciences’ EPS
  3. How Are Gilead Sciences’ Revenues Trending in 2019?
  4. What Are Analysts Recommending for Johnson & Johnson and Gilead?
  5. The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
  6. Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies
  7. This would be the worst-case scenario for health stocks, according to UBS
  8. Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
  9. 3 Big Biotechs Hold Growth Potential in Second Half of 2019
  10. Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
  11. Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
  12. 3 Large-Cap Biotech Stocks to Buy for Massive Gains
  13. Why Gilead could pay more than $2 billion in deal with this small S.F. biotech
  14. Big Drugmakers That May Tread the M&A Path After Pfizer
  15. Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins
  16. Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
  17. 3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences
  18. See what the IHS Markit Score report has to say about Gilead Sciences Inc.
  19. 3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal